OPKO Health is a diversified healthcare company spanning diagnostics and pharmaceuticals. Its BioReference Laboratories unit provides clinical laboratory testing, while the pharmaceutical side includes therapies such as Rayaldee for secondary hyperparathyroidism in chronic kidney disease. The company also holds other healthcare assets and partnerships that extend beyond a single product line.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 149.9 | — | -67.6 | — |
| Q2 2025 | 156.8 | — | -148.4 | — |
| Q3 2025 | 151.7 | — | 21.6 | — |
| Q4 2025 | 148.4 | — | -31.3 | — |
| Q1 2026 | 124.2 | -17.2% | -54.9 | — |
| Q2 2026 | 163.6 | 4.3% | -8.4 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: CRA International, Inc. (CRAI), Middlesex Water Company (MSEX), Aeva Technologies, Inc. (AEVA), Obsidian Therapeutics, Inc. (OBX), Sify Technologies Limited (SIFY), Arteris, Inc. (AIP)